5 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 5 of 5 clinical reviews.
Complete regulatory breakdown of Evenity (romosozumab), including FDA approval history, boxed warning details, compounding legality, EMA status, and post-market safety surveillance data.
FDA approval timeline for Evenity (romosozumab), including the FRAME and ARCH trial context, the boxed warning for cardiovascular risk, label restrictions, and what remains unverified about post-market surveillance.
Evenity's FDA label carries a cardiovascular boxed warning from its April 9, 2019 approval; core wording is unchanged as of May 2026 despite label updates.
A comparison of how the FDA and EMA evaluated romosozumab (Evenity), including label differences, the cardiovascular safety question raised by trial data, and what remains unresolved for prescribers on either side of the Atlantic.
A clinical review of Evenity (romosozumab) patent disputes, FDA regulatory history, boxed warning litigation risk, and the biosimilar pathway for this monoclonal antibody osteoporosis treatment.